Spazgan pills №20

Trade name of the drug: Spazgan

Dosage Form: pills

Composition:

Each pill contains:

active substances:

Metamizole Sodium - 500 mg

Pitofenon hydrochloride - 5.0 mg

fenpiverinium bromide - 0.1 mg;

Excipients:

lactose - 164,000 mg

magnesium stearate - 5,000 mg

colloidal silicon dioxide - 0,100 mg.

Description

Round, flat, with a beveled edge, the pills are white with a slightly yellowish tinge, with a dividing risk on one side and an emblem on the other.

Pharmacotherapeutic group: analgesic non-narcotic and antispasmodic.

Pharmacological properties

The preparation includes: non-narcotic analgesic metamizole sodium (analgin), myotropic antispasmodic pitofenon and m-anticholinergic agent fenpiverinium bromide.

Metamizole is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory effects. Pitofenon, like papaverine, has a direct myotropic effect on the smooth muscles of the internal organs and causes its relaxation. Fenpiverine due to m-anticholinergic action has an additional relaxing effect on smooth muscles.

The combination of the three components of the drug leads to relief of pain, relaxation of smooth muscles, a decrease in elevated body temperature.

Indications

Mild or moderate pain syndrome in spasms of smooth muscles of internal organs - renal and hepatic colic, pain of a spastic nature along the intestines, algomenorrhea. It can be used for short-term symptomatic treatment of pain in the joints, neuralgia, sciatica, myalgia.

As an adjunct, it can be used to reduce pain after surgical and diagnostic procedures.

If necessary, the drug can be used to reduce increased body temperature for colds and infectious and inflammatory diseases.

Contraindications

Hypersensitivity to pyrazolone derivatives (butadion, tribuzone), to other components of the drug. Inhibition of bone marrow hematopoiesis, stable and unstable angina, chronic heart failure decompensation expressed human liver or kidney deficiency of glucose-6-phosphate dehydrogenase, tachyarrhythmia zakratougolnaya form of glaucoma, prostatic hyperplasia with a tendency to urinary retention, ileus and megacolon, granulocytopenia, lactase deficiency, lactose intolerance, glucose-galactose malabsorption, pregnancy, lactation period, children under 8 years of age.

Dosage and administration

Adults and children over 14 years old apply inside (preferably after a meal), usually 1-2 pills 3-4 times a day. The daily dose should not exceed 8 tablets. Reception duration no more than 5 days.

The increase in the daily dose of the drug or the duration of treatment is possible only on the recommendation and under the supervision of a physician.

Dosages for children. In children, the drug is used only on prescription. Dosage for children 8-11 years old - one pill no more than 4 times a day, 12-14 years old - 1 - 1.5 pills no more than 4 times a day. Other dosage regimens are possible only after consulting a doctor.

Precautions for use

Carefully and under the supervision of a physician, the drug should be used in patients with impaired liver or kidney function, with a tendency to hypotension (systolic pressure below 100 mm Hg), bronchospasm, as well as with increased individual sensitivity to nonsteroidal anti-inflammatory drugs or non-narcotic analgesics. With prolonged (more than a week) use of the drug, it is necessary to control the pattern of peripheral blood (white blood cell count) and the functional state of the liver. If you suspect agranulocytosis or in the presence of thrombocytopenia, you must stop taking the drug.

During the period of drug treatment can not take alcohol.

Overdosage

In case of drug overdose, the following symptoms may be observed: vomiting, feeling of dry mouth, change in sweating, disturbance of accommodation, low blood pressure, drowsiness, confusion, impaired liver and kidney function, convulsions.Treatment - gastric lavage, the appointment of Activated carbon, symptomatic therapy.

Adverse Effects

Allergic reactions are possible (urticaria, angioedema); erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome); burning sensation in the epigastric region, dry mouth, headache.

Dizziness, lowering blood pressure, tachycardia, cyanosis, urine staining in red. With prolonged use, thrombocytopenia, leukopenia, agranulocytosis.

Interaction with other drugs

The simultaneous use of SPASGAN with other non-narcotic analgesics can lead to mutual enhancement of toxic effects. Tricyclic antidepressants, oral contraceptives, Allopurinol violate the metabolism of metamizol in the liver and increase its toxicity. Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizol. Simultaneous use with cyclosporine reduces the level of the latter in the blood. Sedatives and tranquilizers enhance the analgesic effect of SPASGAN. If necessary, the simultaneous use of these and other drugs should consult with your doctor.

Use during pregnancy and during breastfeeding

The use of the drug in nursing mothers requires the cessation of breastfeeding.

Special notes

During treatment, it is not recommended to drive vehicles and engage in potentially hazardous activities that require a quick physical and mental response.

Storage conditions

In a dry, dark place, at a temperature not higher than 25 ° C. Keep out of the reach of children!

Vacation conditions

Over the counter